Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials

Background: Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of psoriasis with considerable benefits and a low toxicity. The purpose of this quantitative study was to show high-quality evidence of the efficacy and safety of CHM for the treatment of psoriasis to promote its clinical application.

Methods: Several databases were systematically searched including PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, Chinese Scientific Journals Database, and Wan Fang Database. High-quality randomized controlled trials that compared CHM with non-CHM interventions were included. The RevMan5.3 software was used to calculate risk ratios (RR) at 95% confidence intervals (CI) and conduct the meta-analysis.

Results: Altogether, 1,215 patients participated in this study, including 711 in the experimental group and 504 in the control group. The psoriasis area severity index (PASI) score of the CHM group was significantly lower than that of the placebo group (MD, −4.02; 95% CI, −6.71 to −1.34; p = 0.003). To achieve PASI-60 and PASI-75, the arrival rate of the CHM group was higher than that of the placebo group (PASI-60: RR, 3.52; 95% CI, 1.17 to 10.61; p = 0.03; PASI-75: RR, 9.87; 95% CI, 3.11 to 31.31; p = 0.0001). Furthermore, the efficacy rate was higher in patients receiving CHM than in those receiving placebo (RR, 1.72; 95% CI, 1.01 to 2.93; p = 0.04). The results suggested a greater impact of CHM in improving the dermatology life quality index (DLQI) of patients (MD, −2.12; 95% CI, −3.75 to −0.49; p = 0.01). Regarding pruritus severity, there was no significant difference between the two groups (MD, −1.90; 95% CI, −3.79 to −0.01; p = 0.05). The meta-analysis revealed that the recurrence rate (RR, 0.74; 95% CI, 0.32 to 1.71; p = 0.48) and proportion of adverse events (RR, 1.36; 95% CI, 0.95 to 1.93; p = 0.09) associated with using CHM were similar to those associated with using a placebo.

Conclusion: CHM appears safe and effective in the treatment of psoriasis and has a great positive impact on the DQLI of patients; however, CHM could not completely eliminate skin lesions, improve pruritus severity, and reduce the recurrence rate.

Introduction

Psoriasis is an autoimmune disease characterized by excessive proliferation and abnormal epidermal differentiation at typical body sites, with the plaque type being the most common presentation. It is a chronic, recurrent, inflammatory skin disorder that presents with erythema, papules, and scales, which may be painful and itchy (Griffiths and Barker, 2007; Ramanunny et al., 2020). Approximately 0.51–11.43% of adults and 0–1.37% of children worldwide suffer from psoriasis (Michalek et al., 2017). It is not only a skin disease but has an impact on the patients’ physical and psychological quality of life. Evidence shows an association of psoriasis with arthritis, inflammatory bowel disease (Oliveira et al., 2015), metabolic syndrome (Armstrong et al., 2013), cerebrovascular diseases (Tangtatco and Lara-Carrales, 2017), and mood disorders such as depression and anxiety (Kurd et al., 2010), all of which can be considered comorbidities of psoriasis.

The etiology and pathogenesis of psoriasis has not yet been fully elucidated. It may be related to genetic and environmental factors, and an abnormal immune response. Studies have shown that psoriasis is a true T cell-mediated disease characterized by infiltration of inflammatory cells and excessive proliferation and differentiation of epidermal keratinocytes (KC) (Lowes et al., 2007). In the pathogenesis of psoriasis, KC damage in the epidermis triggers local inflammation, enhances the chemotaxis of T cells and neutrophils, and leads to KC activation and vascular endothelial dysfunction. This stimulates the production of circulating inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ) and vascular endothelial growth factor (VEGF). As a result, mature psoriatic plaques develop by inducing epidermal hyperplasia, epidermal cell proliferation and leukocyte subset recruitment into the skin (Hawkes et al., 2017).

The choice of treatment for psoriasis depends on many factors including the degree of the disease, its impact on the patient's life, and the patient's perception of the disease. At present, the pharmacological treatment includes topical therapy such as emollients, vitamin D₃ derivatives, retinoids, glucocorticoids, and oral therapy such as tretinoins, and immunosuppressants. Additionally, biological therapies are effective for patients with moderate-to-severe psoriasis (Ramanunny et al., 2020). However, most of the therapies used in psoriasis have side effects and are not appropriate for long-term use. Therefore, it is essential that psoriasis treatments remain effective with reduced side effects.

Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of skin diseases and has considerable benefits and a low toxicity (Chen et al., 2018; Ru et al., 2019; Kuai et al., 2020; Li S. et al., 2020; Ru et al., 2020; Yan et al., 2020). The forms of traditional Chinese medicine include topical (cream, oil, emulsion, and ointment) and oral (powder, tablet, capsule, and soup) treatments (Dermatology Branch of Chinese Association of traditional Chinese Medicine, 2013). The syndromes of psoriasis include: 1) blood-heat syndrome, seen in the progressive stage dominated by an inflammatory reaction; 2) blood stasis syndrome, seen in the quiescent stage dominated by hyperplasia of keratinocytes; 3) blood dryness syndrome, seen in the retrogressive stage characterized by skin barrier dysfunction; 4) blazing heat toxin syndrome, seen in the erythroderma or generalized pustule type; 5) damp-heat accumulation syndrome, seen in the localized pustular type; and 6) rheumatic obstruction syndrome, seen in the arthropathy type. All psoriasis syndromes can be transformed and show mixed characteristics between them. In terms of the therapeutic effect, CHM treatment can eliminate skin lesions by removing heat and cooling the blood, nourishing and activating the blood circulation and removing blood stasis, purging fire and providing a detoxification effect, clearing heat and dispelling dampness, dispelling wind and dredge collaterals (Psoriasis Professional Committee of Dermatology and venereology Branch of Chinese Medical Association, 2019).

Evidence from clinical studies suggests that CHMs could reduce the psoriasis area severity index (PASI) score and improve the dermatology life quality index (DLQI) of patients with psoriasis (Bahraini et al., 2018; Zheng et al., 2019). Pharmacological studies demonstrated that Tanshinone IIA, the effective component of danshen (Salvia miltiorrhiza), can inhibit the proliferation of KC, induce apoptosis, and block the cell cycle of KC (Li F. L. et al., 2012). Drugs promoting blood circulation and removing blood stasis such as peach kernel and chuanxiong (Ligusticum chuanxiong Hort.) can dilate blood vessels, increase tissue blood flow, reduce blood viscosity, improve the microcirculation, and hence, promote the regression of skin lesions (Xiao et al., 2019). Additionally, several systematic reviews on the efficacy of CHM in the treatment of psoriasis have been published (Li N. et al., 2012; Deng et al., 2013; Yang et al., 2015; Zhang et al., 2015); however, most are low-quality studies. Moreover, a substantial amount of new data has been published. Therefore, the purpose of this quantitative study was to collect evidence on the efficacy and safety of CHM in the treatment of psoriasis to promote its clinical application.

Methods

This study was conducted in accordance with the Cochrane Handbook on Systematic Review of Interventions and presented in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Guidelines (Liberati et al., 2009) (Additional file: Supplementary Table S1). Additionally, before starting the process, the review was registered in the PROSPERO database (CRD42020204557).

Search Strategy

We searched PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), China Network Knowledge Infrastructure, China Science and Technology Journal Database, and Wan Fang Database from inception to May 31, 2020. We combined medical subject headings and free text words to retrieve all relevant studies. The following keywords were used: (“Psoriasis” OR “Psoriases” OR “Pustulosis Palmaris et Plantaris” OR “Palmoplantaris Pustulosis” OR “Pustulosis of Palms and Soles” OR “Palmoplantaris” OR “Pustulosis” OR “Pustular Psoriasis of Palms and Soles” OR “Parapsoriasis guttata”) and (“Traditional Chinese Medicine” OR “Chung I Hsueh” OR “Hsueh, Chung I” OR “Traditional Medicine, Chinese” OR “Zhong Yi Xue” OR “Chinese Traditional Medicine” OR “Chinese Medicine, Traditional” OR “Chinese drugs” OR “Chinese herbal medicine” OR “Chinese herbal drug”) (Additional file: Supplementary Table S2). Moreover, we searched the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx) and Clinical Trials (http://www.clinicaltrials.gov) websites to identify protocols of high quality randomized controlled trials (RCTs).

Inclusion and Exclusion Criteria

The inclusion criteria were as follows: 1) patients presenting specific diagnostic criteria of psoriasis regardless of age, gender, or ethnicity; 2) RCTs that compared CHM with non-CHM interventions; 3) high-quality RCTs with a Jadad score ≥4 in efficacy and safety analysis; and 4) trials must meet the criteria of double blindness. Studies were excluded if they met the following exclusion criteria: 1) participants with comorbidities; 2) different drug forms used in the experimental and control group; and 3) co-interventions that used anti-psoriatic drugs other than CHM.

Data Extraction

Three researchers (LK, YZ, and XD) carefully screened the qualified articles according to the predetermined inclusion and exclusion criteria. Two researchers (YL and JC) completed the self-designed data extraction form which included the name of the first author, year of publication, sample size, age and gender of participants, duration, intervention of experimental and control group, course of treatment, adverse events, and outcomes.

Outcome Measures

The primary outcome was an improvement of the PASI score after treatment, which is a quantitative rating score that measures the severity of psoriatic lesions based on area coverage and plaque appearance including scaling, infiltration, and erythema. The secondary outcomes included the efficiency, DLQI, visual analog scale (VAS) scores for the intensity of itching, recurrence rate, and adverse events (AEs).

Risk of Bias in Individual Studies

For each included study, two investigators (YL and YR) completed the Jadad scale used specifically for the quality of the evaluation method. A third-party researcher (MX) was consulted whenever there was a disagreement between the two investigators. Four dimensions of the Jadad scale (total seven points) were applied in this research, namely randomization, concealment, blind method, and reports of withdrawals and dropouts. Trials scoring 1–3 points were considered low quality and 4–7 as high quality.

Statistical Analysis

We synthesized the results in the meta-analysis using RevMan5.3 software provided by the Cochrane Collaboration. Risk ratios (RR) with 95% confidence intervals (CI) were evaluated for dichotomous data, continuous data, mean difference (MD), and standard mean difference (SMD) were used. Across the trials, a fixed-effects model was used if there was homogeneity (p >0.1, I²<50%); otherwise, a random-effect model was applied. p values less than 0.05 were considered statistically significant.

Results

Included Studies

We identified 3,943 studies after a preliminary search of six databases; 1,361 repetitive articles were excluded, and 1,699 articles were deleted after reading the titles and abstracts. Among the remaining 883 studies, 407 were excluded since 82 adopted acupuncture in the experimental group, 255 used alternate forms of medicine, 16 adopted single-component herb extracts, seven articles were protocols of RCTs, and 47 used CHM in the control group. Finally, the remaining 476 studies were evaluated using the Jadad scores. Eleven studies with a Jadad scale ≥4 points met the inclusion criteria (Wang, 2003; Zhou, 2011; Zhou, 2012; Chen, 2016; Yao et al., 2016; Li et al., 2017; She, 2017; Lv, 2018; Zhang, 2018; Mao et al., 2019; Li B. Y. et al., 2020). Eight trials were published in Chinese and three in English. The flowchart was created to briefly illustrate the screening process (Figure 1).

FIGURE 1

FIGURE 1. Flowchart of search strategy and study selection, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Study Characteristics

A total of 1,215 patients participated in this study, including 711 in the experimental group and 504 in the control group. All 11 trials used a placebo as control while the forms of the intervention drugs were not identical. Four trials (Zhou, 2011; Zhou, 2012; Zhang, 2018; Mao et al., 2019) used decoctions, four (Yao et al., 2016; She, 2017; Lv, 2018; Zhang, 2018) used particles, one (Li et al., 2017) used ointments, and two (Wang, 2003; Li B. Y. et al., 2020) used capsules. Meanwhile, the treatment course ranged from 4 to 12 weeks.

PASI scores were recorded as the main outcome in all 11 trials: eight reported detailed scores (Wang, 2003; Zhou, 2011; Zhou, 2012; Li et al., 2017; She, 2017; Lv, 2018; Zhang, 2018; Mao et al., 2019), 5 (Chen, 2016; Yao et al., 2016; Li et al., 2017; Lv, 2018; Zhang, 2018) reported the number of patients who achieved PASI-50, 1 (Chen, 2016) reported on PASI-60, 4 (Chen, 2016; Lv, 2018; Zhang, 2018; Li B. Y. et al., 2020) reported on PASI-75, and 2 (Zhang, 2018; Li B. Y. et al., 2020) reported on PASI-90, which signify a PASI score reduction of at least 50, 60, 75, 90%. Three trials (Zhou, 2011; Zhou, 2012; She, 2017) assessed the efficacy rate, three (Zhou, 2012; Lv, 2018; Zhang, 2018) measured DLQI scores, and three reported VAS scores. Only three articles (Yao et al., 2016; Lv, 2018; Mao et al., 2019) calculated the recurrence rates. In terms of safety, adverse events were recorded in all trials. A summary table of preparations and the species or concentration of included CHMs was presented in Table 1.

TABLE 1

TABLE 1. Summary of the characteristics of the included trails.

Description of the Chinese Herbal Medicines

Fifty-four herbs were included in the 11 studies. The top eight most frequently used herbs were used more than 5 times and included the following: Rhizoma Smilacis Glabrae (rhizome of Smilax glabra Roxb), Radix Paeoniae Rubra (root of Paeonia veitchii Lynch), Rhizoma Curcumae Aeruginosae [rhizome of Curcuma zedoaria (Christm.) Roscoe], Radix Salviae Miltiorrhizae (root and rhizome of Salvia miltiorrhiza Bunge), Radix Rehmanniae [root of Rehmannia glutinosa (Gaertn.) DC], Caulis Spatholobi (dried lianoid stem of Spatholobus suberectus Dunn), Radix Arnebiae (root of Lithospermum erythrorhizon Sieb. et Zucc.), Chinese angelica [root of Angelica sinensis (Oliv.) Diels.] (Additional File: Supplementary Table S3).

Risk of Bias

The methodological quality of each study was assessed with the Jadad score and all the included trials appeared to be of high quality, with a Jadad score between 4 and 7. Two trials failed (Wang, 2003; Mao et al., 2019) to report the concealment method, one trial (Li B. Y. et al., 2020) used a randomized method based on the order of patients' visits, two trials (Wang, 2003; Mao et al., 2019) did not describe the method of randomization. More details are shown in Table 2.

TABLE 2

TABLE 2. Jadad scale of the included trials.

Primary Outcomes

PASI Score

We conducted a comprehensive analysis of the PASI scores recorded in eight trials. The PASI score of the CHM group was significantly lower than that of the placebo group after treatment (MD, −4.02; 95% CI, −6.71 to −1.34; p = 0.003) (Figure 2). Additionally, we performed a subgroup analysis based on different PASI reduction indices. For PASI-50 and PASI-90, there were no statistically significant result (PASI-50: RR, 1.53; 95% CI, 0.78 to 3.01; p = 0.21; PASI-90: RR, 3.01; 95% CI, 0.32 to 28.56; p = 0.34). Meanwhile, to achieve PASI-60 and PASI-75, the arrival rate of the CHM group was higher than that of the placebo group (PASI-60: RR, 3.52; 95% CI, 1.17 to 10.61; p = 0.03; PASI-75: RR, 9.87; 95% CI, 3.11 to 31.31; p = 0.0001) (Figure 3).

FIGURE 2

FIGURE 2. Forest plot of PASI Score between CHM and placebo groups. (CHM: Chinese Herbal Medicine; PASI: psoriasis area severity index).

FIGURE 3

FIGURE 3. Forest plot of achievement of PASI-50, PASI-60, PASI-75 and PASI-90between CHM and placebo group. (CHM: Chinese Herbal Medicine; PAIS-50/60/75/90: PASI score decreases more than 50%/60%/75%/90% from baseline).

Secondary Outcome

Efficacy Rate

The efficacy rate was higher in patients receiving CHM than those receiving placebo (RR, 1.72; 95% CI, 1.01 to 2.93; p = 0.04) (Figure 4).

FIGURE 4

FIGURE 4. Forest plot of efficacy rate between CHM and placebo groups. (CHM: Chinese Herbal Medicine).

Dermatology Life Quality Index

Three trials applied the DLQI to assess the quality of life of patients with psoriasis. The comprehensive results suggested a greater impact of CHM than placebo (MD, −2.12; 95% CI, −3.75 to −0.49; p = 0.01) (Figure 5).

FIGURE 5

FIGURE 5. Forest plot of dermatology life quality index (DLQI) score between CHM and placebo group. (CHM: Chinese Herbal Medicine; DLQI: dermatology life quality index).

Pruritus Severity

The visual analogue scale (VAS) was performed to assess pruritus severity. Our meta-analysis indicated that there was no significant difference between the CHM group and the control group (MD, −1.90; 95% CI, −3.79 to −0.01; p = 0.05) (Figure 6).

FIGURE 6

FIGURE 6. Forest plot of VAS score between CHM and placebo group. (CHM: Chinese Herbal Medicine; VAS: visual analog scale).

Recurrence Rate

Only three trials (Yao et al., 2016; Li et al., 2017; Lv, 2018) included follow-up surveys and assessed recurrence rate. The meta-analysis revealed that the recurrence rate associated with CHM was similar that with a placebo (RR, 0.74; 95% CI, 0.32 to 1.71; p = 0.48) (Figure 7).

FIGURE 7

FIGURE 7. Forest plot of recurrence rate between CHM and placebo group. (CHM: Chinese Herbal Medicine).

Safety

All trials assessed AEs including infection, gastrointestinal discomfort, abnormal liver function, limb erythema, and burning heat sensation. Meta-analysis results showed that the incidence of AEs in patients treated with CHM was similar to that of the placebo (RR, 1.36; 95% CI, 0.95 to 1.93; p = 0.09) (Figure 8).

FIGURE 8

FIGURE 8. Forest plot of adverse events between CHM and placebo groups. (CHM: Chinese Herbal Medicine).

Discussion

This systematic review involved 11 randomized controlled trials that evaluated the efficacy and safety of CHM therapy in the treatment of psoriasis. The comprehensive results showed that the PASI score of the CHM group was significantly lower than of the placebo group, while the efficacy rate was higher in the CHM group than in the placebo group. To achieve PASI-50 and PASI-90, the arrival rate of the CHM group was similar to that of the placebo group; however, it was significantly improved for PASI-60 and PASI-75. The results suggested that there may be limited cure of the skin lesions. Indeed, the Chinese guidelines for the diagnosis and treatment of psoriasis (2018 version) pointed out that patients with mild-to-moderate psoriasis are mainly treated with internal CHM treatment, while the severe, pustular, erythrodermic, and arthropathic psoriasis types should be treated with integrated traditional Chinese and western medicine (Psoriasis Professional Committee of Dermatology and venereology Branch of Chinese Medical Association, 2019).

Furthermore, the comprehensive results suggested a greater impact of CHM on the DLQI of patients. On the contrary, there is currently no evidence regarding the efficacy of CHM in reducing episodes of psoriasis relapse and relief pruritus severity. In terms of safety, there was no significant difference between the CHM group and the control group, which indicated that CHM can be safely used for psoriasis.

Psoriasis is a chronic, relapsing skin disease that has psychological and physical effects and substantially impacts the quality of life of patients (Zandi et al., 2011). The most common approach to measure the health-related quality of life (QOL) is psychometric instruments, which measure QOL in many fields; reason why the DLQI is used in dermatology. Our results suggested that the clearance of skin damage by traditional Chinese medicine is effective and safe, and is closely related to improving the quality of life of patients. In addition, the integration of CHM and western medicine has been proven effective. It is known that the treatment of psoriasis in combination with a local sequential therapy can be used to eliminate skin lesions, as well as to relieve itching faster and prolong the therapeutic effect (Yao et al., 2016). Coincidentally, patients who received both a traditional Chinese medicine bath and NB-UVB treatment had a longer remission period (Wang et al, 2020). A systematic review found that oral Chinese medicine was neither better nor inferior to acitretin, which may reduce the common adverse reactions of acitretin. (Zhang et al, 2015).

The 11 studies included 54 herbs, of which the eight most used herbs include the following: Rhizoma Smilacis Glabrae (rhizome of Smilax glabra Roxb), Radix Paeoniae Rubra (root of Paeonia veitchii Lynch), Rhizoma Curcumae Aeruginosae (rhizome of Curcuma zedoaria [Christm.] Roscoe), Radix Salviae Miltiorrhizae (root and rhizome of Salvia miltiorrhiza Bunge), Radix Rehmanniae (root of Rehmannia glutinosa [Gaertn.] DC.), Caulis Spatholobi (dried lianoid stem of Spatholobus suberectus Dunn), Radix Arnebiae (root of Lithospermum erythrorhizon Sieb. et Zucc.) and Chinese angelica (root of Angelica sinensis [Oliv.] Diels.). Generally, the purpose of these traditional Chinese medicines included cooling, activating, and nourishing the blood. The ongoing high-quality randomized controlled double-blind clinical trials are shown in Table 3, which indicated that it is worthy of being investigated to promote clinical application. Pharmacological studies have demonstrated the mechanism of some drugs in the treatment of psoriasis. For instance, Rhizoma smilacis glabrae plays an anti-inflammatory and immunomodulatory role by inhibiting overactivated macrophages and regulating the activity of T lymphocytes (Jiang and Xu, 2003). The main bioactive components of Rhizoma smilacis glabrae, including astilbin, neoastilbin, neoisoastilbin, isoastilbin, engeletin, and isoengeletin are all flavonoids (Zhang et al., 2019). Tanshinone IIA, the effective component of Radix salviae miltiorrhizae, can inhibit the proliferation of KC, induce apoptosis, and block the cell cycle of KC (Li F. L. et al., 2012). Radix arnebiae can be used both internally and externally to treat psoriasis, which decreases IL-17-induced VEGF expression by the inhibition of JAK2/STAT3 signaling and exerts an anti-inflammatory effect via proteasome inhibition (Lu et al., 2011; Xu et al., 2014). Radix paeoniae rubra can inhibit the upregulation of pro-inflammatory mediators, such as tumor necrosis factor-α and IL-1 β (Guo et al., 2012). Pharmacological studies have proved that Caulis spatholobi has the effect of increasing the expression of caspase-3 and inhibiting human neutrophil elastase activity (Ha et al., 2004; Huang et al., 2013). These results demonstrate that the anti-inflammatory and immunomodulatory effects, and inhibition of epidermal cell proliferation by CHM contribute to its efficacy for psoriasis treatment.

TABLE 3

TABLE 3. Chinese Herbal Medicine for Psoriasis in clinical development.

This systematic review has some limitations. First, since we take high-quality RCT research studies as the starting point, satisfying trials with high quality are limited. Moreover, there are no high-quality double-blind placebo RCTs on CHM and Western medicine to better evaluate the efficacy and advantages of CHM. Second, only three trials (Yao et al., 2016; Li et al., 2017; Mao et al., 2019) had been registered in the Clinical Trials Registry Platform. Therefore, it is not possible to use the protocol to confirm no selective reporting. Third, although the methodological quality of the included trials was generally high based on the Jadad scale, there were still some methodological defects. Three (Wang, 2003; Mao et al., 2019; Li B. Y. et al., 2020) trials failed to report the specific randomized method, two trials failed to (Wang, 2003; Mao et al., 2019) report the concealment method, and only three trials (Yao et al., 2016; Li et al., 2017; Lv, 2018) reported the follow-up data. Therefore, the results of these studies should be interpreted carefully. Finally, it was difficult to unify the drug composition, doses and the course of treatment in the included trials. This may affect the validity of the research results. A large high-quality RCT with sufficient standardized information on the quality control, content, usage, and course of treatment of CHM should be conducted in future studies (Gagnier et al., 2006).

Conclusion

In summary, CHM appears safe and effective in treating patients with psoriasis and has a great impact in improving their quality of life, but does not lead to complete elimination of skin lesions and improvement in pruritus severity. No evidence is available on the ability of CHM to reduce the relapse the rate of psoriasis. All the included studies reported adverse events; overall, CHM was safe for the treatment of psoriasis.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author Contributions

YL and JC conceived this study. YL and JC designed this study. LK, YZ, and XD searched the literature and extracted data. YL, YR, and MX assessed the quality of trials and analyzed the data. XS and BL prepared the original manuscript draft. YR, MX and XD contributed to revise the manuscript. All authors have read and approved the final manuscript.

Funding

This study was supported by the National Key Research and Development Program of China (No. 2018YFC1705301), the National Natural Science Foundation of China (No. 81973860, 81904214, 81874470, 82074427, 82004235), the Shanghai Key Clinical Specialty Construction Project (No. shslczdzk05001), the Shanghai Three-year Action Plan for the Development of Traditional Chinese Medicine (No. ZY(2018-2020)-FWTX-4010, ZY(2018-2020)-FWTX-1008), the Shanghai Pujiang Talent Plan (No. 2020PJD067) and the Shanghai Science and Technology Commission (No. 20YF1450400, 18401932300).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.599433/full#supplementary-material.

Abbreviation

AEs, adverse events; CENTRAL, Cochrane Central Registry of Controlled Trials; ChiCTR: Chinese Clinical Trial Registry; CHM, Chinese herbal medicine; CNKI, China Network Knowledge Infrastructure; CQVIP, China Science and Technology Journal Database; DLQI, dermatology life quality index; IL-17, interleukin-17; IL-6, interleukin-6; IL-1β, interleukin-1β; IFN-γ, Interferon-γ; KC, keratinocytes; MeSH, medical subject headings; PASI, psoriasis area severity index; PASI-50/60/75/90, PASI score decreases more than 50%/60%/75%/90% from baseline; PRISMA, preferred reporting items for systematic review and meta-analyses; RCTs, randomized control trials; RER, recurrence rate; TNF-α, tumor necrosis factor-α; VAS, visual analog scale; VEGF, vascular endothelial growth factor.

References

Armstrong, A. W., Harskamp, C. T., and Armstrong, E. J. (2013). Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J. Am. Acad. Dermatol. 68, 654–662. doi:10.1016/j.jaad.2012.08.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Bahraini, P., Rajabi, M., Mansouri, P., Sarafian, G., Chalangari, R., and Azizian, Z. (2018). Turmeric tonic as a treatment in scalp psoriasis: a randomized placebo-control clinical trial. J. Cosmet. Dermatol. 17, 461–466. doi:10.1111/jocd.12513

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, W. W. (2016). Study on the treatment of Psoriasis Vulgaris from Blood and Serum metabonomics. Master’s thesis. Beijing (China): Beijing University of Chinese Medicine. [in Chinese].

Google Scholar

Chen, Y., Guo, D. J., Deng, H., Wu, M. F., Zhang, Y. N., Li, S., et al. (2018). Acute and chronic toxicity of a polyherbal preparation - jueyin granules. BMC Compl. Alternative Med. 18, 148. doi:10.1186/s12906-018-2211-z

CrossRef Full Text | Google Scholar

Deng, S., May, B. H., Zhang, A. L., Lu, C., and Xue, C. C. L. (2013). Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis. Arch. Dermatol. Res. 305, 179–189. doi:10.1007/s00403-013-1316-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Dermatology Branch of Chinese Association of traditional Chinese medicine (2013). Evidence-based clinical practice guide of traditional Chinese medicine for psoriasis vulgaris. J. Tradit. Chin. Med. 55, 76–82. doi:10.13288/j.11-2166/r.2014.01.021

CrossRef Full Text | Google Scholar

Gagnier, J. J., Boon, H., Rochon, P., Moher, D., Barnes, J., and Bombardier, C. (2006). CONSORT Group.Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann. Intern. Med. 144, 364–367. doi:10.7326/0003-4819-144-5-200603070-00013

PubMed Abstract | CrossRef Full Text | Google Scholar

Griffiths, C. E., and Barker, J. (2007). Pathogenesis and clinical features of psoriasis. Lancet 370, 263–271. doi:10.1016/S0140-6736(07)61128-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Guo, R. B., Wang, G. F., Zhao, A. P., Gu, J., Sun, X. L., and Hu, G. (2012). Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-кB-mediated inflammatory responses. PLoS One 7, e49701. doi:10.1371/journal.pone.0049701

PubMed Abstract | CrossRef Full Text | Google Scholar

Ha, E. S., Lee, E. O., Yoon, T. J., Kin, J. H., Park, J. O., Lim, N. C., et al. (2004). Methylene chloride fraction of Spatholobi Caulis induces apoptosis via caspase dependent pathway in U937 cell. Biol. Pharm. Bull. 27, 1348–1352. doi:10.1248/bpb.27.1348

PubMed Abstract | CrossRef Full Text | Google Scholar

Hawkes, J. E., Chan, T. C., and Krueger, J. G. (2017). Psoriasis pathogenesis and the development of novel targeted immune therapies. J. Allergy Clin. Immunol. 140, 645–653. doi:10.1016/j.jaci.2017.07.004

PubMed Abstract | CrossRef Full Text | Google Scholar

Huang, Y., Chen, L., Feng, L., Guo, F., and Li, Y. (2013). Characterization of total phenolic constituents from the stems of Spatholobus suberectus using LC-DAD-MS(n) and their inhibitory effect on human neutrophil elastase activity. Molecules 18, 7549–7556. doi:10.3390/molecules18077549

PubMed Abstract | CrossRef Full Text | Google Scholar

Jiang, J., and Xu, Q. (2003). Immunomodulatory activity of the aqueous extract from rhizome of Smilax glabra in the later phase of adjuvant-induced arthritis in rats. J. Ethnopharmacol. 85, 53–59. doi:10.1016/s0378-8741(02)00340-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Kuai, L., Song, J., Zhang, R., Xing, M., Luo, Y., Ru, Y., et al. (2020). Uncovering the mechanism of jueyin granules in the treatment of psoriasis using network pharmacology. J. Ethnopharmacol. 262, 113214. doi:10.1016/j.jep.2020.113214

PubMed Abstract | CrossRef Full Text | Google Scholar

Kurd, S. K., Troxel, A. B., Crits-Christoph, P., and Gelfand, J. M. (2010). The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch. Dermatol. 146, 891–895. doi:10.1001/archdermatol.2010.186

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, F. L., Xu, R., Zeng, Q. C., Li, X., Chen, J., Wang, Y. F., et al. (2012). Tanshinone IIA inhibits growth of keratinocytes through cell cycle arrest and apoptosis: underlying treatment mechanism of psoriasis. Evid. Based Compl. Alternat. Med. 2012, 927658. doi:10.1155/2012/927658

CrossRef Full Text | Google Scholar

Li, N., Li, Y. Q., Li, H. Y., Guo, W., and Bai, Y. P. (2012). Efficacy of externally applied Chinese herbal drugs in treating psoriasis: a systematic review. Chin. J. Integr. Med. 18, 222–229. doi:10.1007/s11655-012-1004-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, N., Zhao, W. B., Xing, J. M., Liu, J. P., Zhang, G. Z., Zhang, Y. B., et al. (2017). Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial. BMC Compl. Alternat. Med. 17, 264. doi:10.1186/s12906-017-1631-5

CrossRef Full Text | Google Scholar

Li, B. Y., Sun, H. Y., Wu, M., Yan, X. X., Yu, M. L., Zhang, C. X., et al. (2020). A Single-Center randomized double-blind placebo-controlled clinical trial of Kunxian capsule in the treatment of psoriasis vulgaris. Chin J Lep Skin Dis. 36, 161–164. doi:10.12144/zgmfskin202003161

CrossRef Full Text | Google Scholar

Li, S., Zhang, C., Zhang, H. Y., Zhang, H. Y., Zhou, M., Wang, S. N., et al. (2020). Efficacy and safety of jueyin granules for patients with mild-to-moderate psoriasis vulgaris: protocol for a multicenter randomized placebo-controlled trial. Evid. Based Compl. Alternat. Med. 2020, 8942301. doi:10.1155/2020/8942301

CrossRef Full Text | Google Scholar

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 21, b2700. doi:10.1136/bmj.b2700

CrossRef Full Text | Google Scholar

Lowes, M. A., Bowcock, A. M., and Krueger, J. G. (2007). Review article pathogenesis and therapy of psoriasis. Nature 445, 866–873. doi:10.1038/nature05663

PubMed Abstract | CrossRef Full Text | Google Scholar

Lu, L., Qin, A. P., Huang, H. B., Zhou, P., Zhang, C. Y., Liu, N. N., et al. (2011). Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur. J. Pharmacol. 658, 242–247. doi:10.1016/j.ejphar.2011.02.043

PubMed Abstract | CrossRef Full Text | Google Scholar

Lv, M., (2018). Clinical observation and mechanism exploration of PSORI-CM02, Yinxieling tablet on stable plaque psoriasis. Master’s thesis. Guangzhou (China): Guangzhou University of Chinese Medicine [in Chinese].

Google Scholar

Mao, C. L., Wu, Y. Y., Zhou, D. M., Xu, W. J., and Wang, J. S. (2019). The efficiency and safety of the Chinese herbal medicine liang xue huo xue decoction (LXHXD) in patients with psoriasis vulgaris of blood heat syndrome. Int. J. Clin. Exp. Med. 12, 6020–6025.

Google Scholar

Michalek, I. M., Loring, B., and John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol. 31, 205–212. doi:10.1111/jdv.13854

CrossRef Full Text | Google Scholar

Oliveira, M. F. S. P., Rocha, B. O., and Duarte, G. V. (2015). Psoriasis: classical and emerging comorbidities. Anais Brasileiros De Dermatologia. 90, 9–20. doi:10.1590/abd1806-4841.20153038

PubMed Abstract | CrossRef Full Text | Google Scholar

Psoriasis Professional Committee of Dermatology and venereology Branch of Chinese Medical Association (2019). Guidelines for the diagnosis and treatment of Psoriasis in China (2018 simplified version). Chin. J. Dermatol. 52, 223–230. doi:10.3760/cma.j.issn.0412-4030.2019.04.001

CrossRef Full Text | Google Scholar

Ramanunny, A. K., Wadhwa, S., Singh, S. K., Sharma, D. S., Khursheed, R., and Awasthi, A. (2020). Treatment strategies against psoriasis: principle, perspectives and practices. Curr. Drug Deliv. 17, 52–73. doi:10.2174/1567201816666191120120551

PubMed Abstract | CrossRef Full Text | Google Scholar

Ru, Y., Li, H., Zhang, R., Luo, Y., Song, J., Kuai, L., et al. (2020). Role of keratinocytes and immune cells in the anti-inflammatory effects of Tripterygium wilfordii Hook. f. in a murine model of psoriasis. Phytomedicine 77, 153299. doi:10.1016/j.phymed.2020.153299

PubMed Abstract | CrossRef Full Text | Google Scholar

Ru, Y., Yan, X. N., Yang, Q. S., Gong, L. P., Li, L. E., Chen, J., et al. (2019). Oral Taodan granules for mild-to-moderate psoriasis vulgaris: protocol for a randomized, double-blind, multicenter clinical trial. Ann. Transl. Med. 7, 488. doi:10.21037/atm.2019.09.05

PubMed Abstract | CrossRef Full Text | Google Scholar

She, Y. Y. (2017). A Clinical research on the treatment of psoriasis vulgaris in stationary stag blood dryness syndrome, blood stasis syndrome with Calm-the-Mind-and-Relieve-Intching formula. Master’s thesis. Beijing (China): China Academy of Chinese Medicine Sciences [in Chinese].

Google Scholar

Tangtatco, J. A. A., and Lara-Corrales, I. (2017). Update in the management of pediatric psoriasis. Curr. Opin. Pediatr. 29, 434. doi:10.1097/MOP.0000000000000517

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, G., Bai, F., Tian, Z., Fan, L., and Lei, M. (2020). Balneotherapy with Chinese herbal medicine prolongs the remission period in patients with psoriasis vulgaris. Dermatol. Ther. 33, e13351. doi:10.1111/dth.13351

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, Z. C. (2003). Compound Indigo Naturalis Capsules for the treatment of psoriasis: a randomised controlled trial. J Chin Tolk Ther. 11, 48–49. doi:10.3969/j.issn.1007-5798.2003.01.077

CrossRef Full Text | Google Scholar

Xiao, M., Qian, C. Y., Luo, X., Yang, M. B., Zhang, Y. F., Wu, C. Y., et al. (2019). Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats. J. Ethnopharmacol. 235, 100–110. doi:10.1016/j.jep.2019.01.040

PubMed Abstract | CrossRef Full Text | Google Scholar

Xu, Y., Xu, X., Gao, X., Chen, H., and Geng, L. (2014). Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway. Int. Immunopharm. 19, 327–333. doi:10.1016/j.intimp.2014.01.027

CrossRef Full Text | Google Scholar

Yan, J. T., Wang, Q. G., Liu, X. Q., Li, B., Ru, Y., Hong, S., et al. (2020). The immune status of patients with psoriasis vulgaris of blood-stasis syndrome and blood-dryness syndrome: a qualitative evidence synthesis. Ann. Palliat. Med. 9,1382–1395. doi:10.21037/apm-19-432

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, L., Zhang, C. S., May, B., Yu, J., Guo, X., Zhang, A. L., et al. (2015). Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. Chin. Med. 10, 27. doi:10.1186/s13020-015-0060-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Yao, D. N., Lu, C. J., Wen, Z. H., Yan, Y. H., Xuan, M. L., Li, X. Y., et al. (2016). Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. Trials 17, 140. doi:10.1186/s13063-016-1272-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Zandi, S., Meymandi, S. S., Gorji, S. H., and Shahrebabak, F. S. (2011). Evaluation of quality of life in patients with psoriasis. Dermatol. Cosmet. 2, 166–173.

Google Scholar

Zhang, C. S., Yu, J. J., Parker, S., Parker, S., Zhang, A. L., May, B., et al. (2015). Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. Int. J. Dermatol. 53, 1305–1318. doi:10.1111/ijd.12607

CrossRef Full Text | Google Scholar

Zhang, L., Zheng, D., and Zhang, Q. F., (2019). Purification of total flavonoids from Rhizoma Smilacis Glabrae through cyclodextrin-assisted extraction and resin adsorption. Food Sci. Nutr. 7, 449–456. doi:10.1002/fsn3.809

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, Z. Z. (2018). Effect of treatment and mechanism with Chinese medicine PSORI-CM01, balneotherapy and coal tar on psoriasis vulgaris. Master’s thesis. Guangzhou (China): Guangzhou University of Chinese Medicine [in Chinese].

Google Scholar

Zheng, Q., Jiang, W. C., Sun, X. Y., Ma, T., Xu, W. B., and Shen, F. (2019). Total glucosides of paeony for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 62: 152940. doi:10.1016/j.phymed.2019.152940

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, D. M. (2011). Wang Jusheng's academic thoughts and clinical experiences and the clinical study of treating psoriasis through blood differentiation. Master’s thesis. Beijing (China): Beijing University of Chinese Medicine [in Chinese].

Google Scholar

Zhou, M. J. (2012). Study of the Mechanisms of Liangxuehuoxue Complex Prescription on Progressive Psoriasis. Master’s thesis. Dalian (China): Dalian Medical University.

Google Scholar